Skip to content

Study · Animal study (in vivo) · mouse · 2022

7 results

GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.

Unterberger CJ, Maklakova VI, Lazar M, Arneson PD, Mcilwain SJ, Tsourkas PK, Hu R, Kopchick JJ, Swanson SM, Marker PC

Endocrinology1 May 2022Cited by 10 (Europe PMC)

PMID35383352 (opens in a new tab)PMCIDPMC8995093 (opens in a new tab)DOI10.1210/endocr/bqac031 (opens in a new tab)PepBankPUB-35383352
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with Pten-mutant prostate cancer xenografts, pegvisomant reduced xenograft size.

    In plain wordsIn mice with prostate cancer xenografts, pegvisomant reduced tumor size.

    Peptide
    Pegvisomant
    Outcome
    DecreaseXenograft size
    Study

    mousen: not reported in source

    Pten-mutant prostate cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When Pten-mutant cells were grown as xenografts in mice, pegvisomant treatment dramatically reduced xenograft size, and this was accompanied by decreased proliferation and increased apoptosis.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with Pten-mutant prostate cancer xenografts, pegvisomant decreased proliferation.

    In plain wordsIn mice with prostate cancer xenografts, pegvisomant decreased proliferation.

    Peptide
    Pegvisomant
    Outcome
    DecreaseProliferation
    Study

    mousen: not reported in source

    Pten-mutant prostate cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When Pten-mutant cells were grown as xenografts in mice, pegvisomant treatment dramatically reduced xenograft size, and this was accompanied by decreased proliferation and increased apoptosis.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with Pten-mutant prostate cancer xenografts, pegvisomant increased apoptosis.

    In plain wordsIn mice with prostate cancer xenografts, pegvisomant increased cancer cell death.

    Peptide
    Pegvisomant
    Outcome
    IncreaseApoptosis
    Study

    mousen: not reported in source

    Pten-mutant prostate cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When Pten-mutant cells were grown as xenografts in mice, pegvisomant treatment dramatically reduced xenograft size, and this was accompanied by decreased proliferation and increased apoptosis.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mouse prostate cancer xenografts, pegvisomant upregulated 1765 genes.

    In plain wordsIn mice with prostate cancer xenografts, pegvisomant increased expression of 1765 genes.

    Peptide
    Pegvisomant
    Outcome
    IncreaseUpregulated genes
    Study

    mousen: not reported in source

    Prostate cancer xenografts
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Measurements

    Upregulated genes
    1765 genes
    pegvisomant treatment

    Source sentences

    Summary
    RNA sequencing of xenografts identified 1765 genes upregulated and 953 genes downregulated in response to pegvisomant, including many genes previously implicated as cancer drivers.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mouse prostate cancer xenografts, pegvisomant downregulated 953 genes.

    In plain wordsIn mice with prostate cancer xenografts, pegvisomant decreased expression of 953 genes.

    Peptide
    Pegvisomant
    Outcome
    DecreaseDownregulated genes
    Study

    mousen: not reported in source

    Prostate cancer xenografts
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Measurements

    Downregulated genes
    953 genes
    pegvisomant treatment

    Source sentences

    Summary
    RNA sequencing of xenografts identified 1765 genes upregulated and 953 genes downregulated in response to pegvisomant, including many genes previously implicated as cancer drivers.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mouse prostate cancer models, selected genes showed similar pegvisomant regulation in vivo and in vitro, while others responded only in vivo.

    In plain wordsIn mouse prostate cancer models, some genes responded similarly across settings, while others responded to pegvisomant only in animals.

    Peptide
    Pegvisomant
    Outcome
    MixedContext-dependent gene regulation
    Study

    mousen: not reported in source

    Prostate cancer xenografts
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    some genes exhibited similar regulation by pegvisomant in prostate cancer cells whether treatment was in vivo or in vitro, indicating direct regulation by GH via GHR activation in prostate cancer cells, whereas other genes responded to pegvisomant only in vivo
  7. 07LabIn vitro (cells)Efficacy outcome

    In mouse Pten-deletion prostate cancer cells, pegvisomant reduced cell growth.

    In plain wordsIn cells from mouse prostate cancers, pegvisomant reduced cell growth.

    Peptide
    Pegvisomant
    Outcome
    DecreaseCell growth
    Study

    mousen: not reported in source

    Mouse Pten-deletion prostate cancer cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro cell growth was stimulated by GH and reduced by pegvisomant.
    1 context sentence
    Summary · context
    The present study addresses the species specificity of GH-GHR activity by investigating GH actions in prostate cancer cell lines derived from a mouse Pten-deletion model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.